D uring coronary angiography and vascular intervention, eg, percutaneous transluminal coronary angioplasty (PTCA), many factors may cause platelet activation and degranulation. Exposure of highly thrombogenic subendothelial collagen and local thrombin generation occur on rupture of the atherosclerotic plaque during PTCA,1 and these will promote platelet recruitment and cause platelet degranulation. Any procedural factor that would increase the susceptibility of the circulating platelets to these agonists and cause increased platelet degranulation would promote the thrombotic tendency and the local release of growth factors (eg, platelet-derived growth factor, PDGF) within the damaged coronary artery lumen.
Contrast media used to opacify vessels during angiography can be divided into three groups by virtue of their osmolality and their ionic nature (Table 1) . It media (LOCM) are associated with fewer side effects and have the advantage of causing less nausea and vomiting than the high osmolality ionic contrast media.2'3 There have, however, been several reports of increased thrombotic complications with nonionic LOCM during diagnostic cardiac catheterization4'5 and coronary angioplasty.6 '7 Paradoxically, contrast media are known to have an anticoagulant effect that has been widely investigated.
Ionic contrast media have been found to be more anticoagulant than nonionic contrast media, and this has been suggested as a possible reason for the higher incidence of thrombotic events reported with nonionic contrast media.8 It has been proposed that ionic contrast media may delay coagulation by inhibiting thrombin formation and fibrin polymerization.9,10 Studies in vitro have shown decreased fibrinopeptide A and thrombin-antithrombin complex formation."1 The lesser anticoagulant effects of nonionic contrast media do not appear to operate via this mechanism12 and may depend on the osmolality and chemical structure of the iodinated molecules.
The effects of contrast media on platelets are unclear. Contrast media have been found to have an inhibitory effect on ex vivo platelet aggregation in patients within 20 minutes of angiography. In humans, there is a rapid This study investigated the effects of three routinely used contrast media on platelet activation and degranulation as assessed by immunolabeling and flow cytometric techniques in blood samples from both normal subjects and patients pretreated with heparin and aspirin before routine PTCA.
Methods

Reagents
Antibodies. Platelets were identified by labeling with pan platelet MAbs to GPIb, (RFGP37) and GPIIb-IIIa (RFGP56) raised in our laboratory.24 These antibodies were purified from mouse ascitic fluid by ammonium sulphate precipitation followed by DEAE also taken from three patients at the Royal Brompton National Heart and Lung Hospital (RBNHLH) who were undergoing PTCA for symptomatic coronary heart disease before injection of any contrast media or placement of intraaortic guide catheters. All patients were on long-term aspirin therapy (300 mg per day) and were anticoagulated with 15 000 U of heparin to achieve an activated clotting time of >300 seconds or PTTK >400 seconds. A blood sample was also obtained from a patient with type I Glanzmann's thrombasthenia, a hereditary lack of the platelet membrane GPIIb-IIIa complex.28 Ethical committee approval was given by the RFHSM for use of normal volunteer blood and by the RBNHLH for use of patients' blood.
Blood was collected from the anticubital fossa, with minimal stasis, via a 21-gauge butterfly needle. The first 2 mL were taken into EDTA and used to determine the full blood count. Subsequent 5-mL samples were taken directly into 10-mL syringes (Plastipak, Becton Dickinson) containing volumes of contrast media ranging from 0.5 to 5 mL. An additional syringe containing 5 mL of 0.9% (wt/vol) saline was used as the standard control for each of the experiments.
Monovette tubes (Sarstedt Ltd, Leicester, England) containing 0.5 mL of 3.8% tri-sodium citrate. Within 2 minutes, these blood/contrast media mixtures were immunolabeled for flow cytometric analysis using a modification of the methods described by Warkentin et al19 and Janes et al. 29 Five microliters of the blood/ contrast media mixtures was added to LP3 tubes containing 50 ,uL of HEPES-buffered saline (0.145 M NaCI, 5 mM KCl, 1 mM MgSO4, 10 mM HEPES; pH 7.4) to which had been added 5-,uL aliquots of appropriate concentrations of antibodies and agonists. After gentle mixing, the samples were incubated without stirring for a further 20 minutes, then diluted and fixed with 0.5 mL of 0.2% formyl saline (0.2% formaldehyde in 0.9% NaCl) to inhibit further activation. Samples analyzed for fibrinogen receptor expression were first incubated with 5 gL of PAC-1 for 15 minutes, then R-anti-MIg-FITC was added for a further 15 minutes. All incubations were carried out at room temperature (220 to 26°C), and all samples were assayed in duplicate.
Flow Cytometric Analysis
Samples were analyzed within 2 hours of collection in a Coulter EPICS Profile II flow cytometer (Coulter Electronics Ltd, Luton, England). The instrument was aligned daily with "Immunocheck" and "Standard Brite" beads (Coulter Immunology) to calibrate the light scatter and fluorescence parameters, respectively. The platelet population was identified by its light scatter characteristics and identity confirmed using the antiGPIb MAb, RFGP37-FITC. An electronic bit map was set around the platelet population, and >98% of the particles analyzed in all samples were positive for GPIb. The negative cut-off levels for each sample were set at 2% using appropriate isotype controls as described at Janes et al. 29 Five thousand platelets were analyzed in each sample, and the data were expressed as the percentage of cells positive for fluorescent antibody binding.
Detection of /3TG and PF4 Release by Contrast Media
Five-milliliter samples of blood were collected from normal volunteers into 10-mL syringes containing 5 mL of contrast medium or saline. After a 1-minute incubation, 5 mL of each blood/contrast media mixture was added to citrate and processed for flow cytometry as described above, and 5 mL was transferred into precooled Diatubes (Diagnostica Stago) containing a mixture of sodium citrate and citric acid with theophylline, adenosine, and dypyrimadole. These were left on ice for 15 minutes and then centrifuged at 2500g for 30 minutes at 4°C. Samples of the plasma/contrast media mixtures were aspirated from the tubes, aliquotted, and frozen at -70°C for subsequent analysis of f3TG and PF4 using the Asserachrom 6TG and PF4 ELISA kits (Diagnostica Stago).
Results
Flow Cytometric Analysis of Platelets
Identification of the platelet population in the flow cytometer is illustrated in Fig 1. 
Effect of Contact Time and Concentration of Contrast Media
The local concentration of contrast media in the coronary vessel during angiography will vary according to the time after contrast injection. Initially, the vessel is filled with contrast medium during injection and the contrast media concentration is at least 1:1 with blood.
Subsequently, the ratio changes with resumption of blood flow. If a dissection is caused, however, contrast medium can become trapped in the wall of the coronary artery increasing the contact time with the whole blood.
The effect of prolonged incubation on the degree of degranulation seen with each contrast medium is shown in Fig 3. Equal volumes of contrast media and blood a) P-selectin The ratio of contrast media mixed with blood was varied between 1:1 and 1:10 by taking 5 mL of blood into syringes containing volumes of contrast media between 0.5 and 5 mL (Fig 4) . The ( Table 3 ). Addition of 0.4 U/mL of thrombin to the control (normal saline) samples, however, showed that the thrombin antagonists were effective in blocking thrombin-induced platelet degranulation.
Effect of Osmolality on Platelet Degranulation
The three contrast media studied had significant differences in their osmolality (Table 1 ). To assess whether the different effects of contrast media on platelets could be explained by the osmolality of the contrast media alone, solutions of equivalent osmolality and ionic composition were prepared and incubated with equal volumes of whole blood in the standard method outlined above. Table 4 shows the degree of platelet degranulation occurring with each of the contrast media and the solutions of equivalent osmolality and ionic strength. The with Hexabrix and then added to assay tubes containing thrombin at concentrations ranging from 0.01 to 0.2 U/mL. Fig 7 shows that Hexabrix markedly reduced thrombin-induced degranulation of the platelets at all agonist concentrations. In the control sample, (0.9% saline), thrombin caused platelets to express P-selectin and CD63 (Fig 7) in a concentration-dependent manner, rising to a maximum at 0.2 U/mL of thrombin. Hexabrix totally inhibited this effect at thrombin concentrations up to 0.05 U/mL and at maximum thrombin (0.2 U/mL). P-selectin was seen on only 45% of platelets compared with 93% in the control, whereas CD63 was seen on only 43% compared with 85% in the control. When platelets were stimulated with the 14 amino acid thrombin receptor activation peptide (TRAP), however, Hexabrix did not inhibit the expression of P-selectin or CD63 antigen. For example, at maximum TRAP concentration (1 x 10-4 M), 92.7% of platelets in the control samples expressed P-selectin compared with 89.7% in the blood incubated with Hexabrix.
Discussion
Although the anticoagulant properties of angiographic contrast media have been studied extensively,8-12,14 their effects on platelets have received less attention and the findings have been contradictory, reporting both increases in BTG and PF4 release in vivo14 and decreases in serotonin in vitro. 13 Platelet aggregation has been reported to be inhibited ex vivo13,14 and in vitro.0 In addition, the differences between the types of contrast agents have not been fully investigated.
Flow cytometric examination of platelet activation marker expression allows such discrepancies to be resolved. The activation status of individual platelets, within the whole platelet population, can be examined directly. In addition, the use of whole blood flow cytometry avoids the need for fixatives that are required to prevent artifactual platelet activation occurring during the separation and washing procedures, and this lack of fixatives allows the in vitro response of the platelets to agonists or other agents to be assessed.
The present in vitro study has demonstrated significant differences in effects on platelets in native blood of three commonly used types of contrast media. The nonionic LOCM (Omnipaque) caused profound platelet degranulation as evidenced by the expression of the a-granule and lysosomal membrane antigens on the platelet surface, which was paralleled by a marked release of fTG and PF4. The two ionic contrast media caused less platelet degranulation than the nonionic LOCM, but while the HOCM Urografin still produced some degranulation, after 1 minute incubation, which increased in prolonged exposure, the LOCM Hexabrix caused no platelet degranulation even after 30 minutes incubation with blood and minimal release of BTG and PF4 similar to that seen with the controls. In most studies on the effects of contrast media on platelets, the contact times have ranged from 20 minutes to several hours.14 The present study indicates that platelet degranulation occurs within the first minute of exposure of the blood to the contrast media.
The differences between the three contrast media could not be accounted for by possible inhibitory effects on antibody binding. Platelets incubated with equal volumes of contrast media showed no difference in the binding of the MAbs to the GPIb-IX and GPIIb-IIIa complexes, present on all platelets, compared with that seen in control samples; nor were their effects related solely to the osmolality of the media, as there was no direct correlation between osmolality and their plateletdegranulating effects.
The effects of the contrast media on platelets were linked more closely to the ionic nature of the media; solutions of similar osmolality and ionic strength produced very similar effects on platelets to their contrast media equivalents. However, when solutions of similar ionic strength were compared, increasing osmolality appeared to contribute to the degree of platelet degranulation seen. Optiray, another nonionic contrast medium, caused a similar degree of platelet degranulation to Omnipaque (data not shown), suggesting that the effects seen were linked to the nonionic chemical properties of the contrast media. This was further confirmed by the finding that the nonionic control manitol caused a similar degree of platelet degranulation to that seen with the nonionic contrast medium Omnipaque. Together, these data indicate that it is the nonionic molecules per se that directly affect the platelets, implying that any contrast media based on nonionic molecules would be likely to cause platelet degranulation.
The platelet degranulation induced by the nonionic LOCM and by the ionic HOCM appeared to be independent of activation of the GPIIb-IIIa complex and of fibrinogen binding. Studies on a patient with Glanzmann's thrombasthenia showed that despite this absence of the GPIIb-IIIa receptor complex, both contrast media caused a similar degree of platelet degranulation to that seen with normal volunteer blood and to that seen when the blood from this patient was stimulated with thrombin.
The observation that contrast media cause minimal activation of the platelet GPIIb-IIIa receptor may help explain why the aggregation studies have been relatively uninformative. Platelets require fibrinogen binding to the activated GPIIb-IIIa receptor for platelet aggregation to occur. Even at the highest concentrations of contrast media, only a small increase in the fibrinogen receptor activation was seen, and this was to a level below that required for platelet aggregation to occur. The somewhat contradictory observation that the contrast media can inhibit platelet aggregation may be related to their viscosity, acting to slow down plateletplatelet contact and hence the rate of aggregation. The concentrations at which the nonionic LOCM and the ionic HOCM caused degranulation (>1:10 and >1:3, respectively), although markedly different, are concentrations that can be present, albeit transiently, during angiography and opacification of the coronary artery. During coronary intervention, the process of balloon dilatation causes local stretching of the narrowed section of atherosclerotic vessel. This barotrauma can cause significant micro-and macrodissections within the wall of the coronary artery. This is followed by injection of contrast media into the lumen of the balloon damaged vessel to allow angiographic assessment of the result of the angioplasty. Within the PTCA-induced dissections, high concentrations of contrast media can occur, and the contrast media remain relatively static because of decreased flow. A nonionic contrast medium and to a lesser extent an ionic HOCM would potentially cause significant platelet degranulation within such a dissection flap in the vessel wall.
Patients undergoing routine PTCA are normally fully anticoagulated with heparin and receive standard-dose aspirin therapy. We have previously shown that aspirin itself does not affect the platelet degranulation process in response to ADP and thrombin per se.31 Incubation of contrast media with blood from fully anticoagulated patients caused a similar pattern of platelet degranulation to that seen with the normal volunteers. The nonionic LOCM caused marked platelet degranulation, suggesting that the pretreatment of patients undergoing PTCA with aspirin and heparin will not modify this marked platelet degranulation and that the nonionic LOCM does not stimulate the platelets through a thrombin mediated mechanism.
To confirm this and to test whether the contrast media had a heparin-neutralizing effect that would thus allow thrombin generation to occur in the samples, blood from normal volunteers was pretreated with thrombin antagonists before addition to contrast media. Neither hirudin nor PPACK abolished the degranulation induced by Omnipaque or Urografin, suggesting that the degranulation is not mediated simply by the production of thrombin in blood exposed to the contrast medium, in accord with observation of the effects of the agents on the coagulation cascade. [9] [10] [11] Although the activation caused by the nonionic LOCM appears to be independent of thrombin, high levels of local intracoronary thrombin generation in response to vessel wall injury and clot bound thrombin could independently cause platelets to degranulate. In this study we have shown that Hexabrix has a marked inhibitory effect on thrombin induced platelet degranulation, confirming an earlier report by Matsuda et al. 30 Thrombin acts on the platelet thrombin receptor as a protease, cleaving the N-terminus of the extracellular domain of the receptor. The newly exposed N-terminal can then act as an autologous tethered ligand. This effect can be mimicked by a synthetic peptide analog of this ligand (thrombin receptor activating peptide, TRAP).27 Activation of platelets by TRAP was unaffected by the presence of Hexabrix. This suggests that the action of thrombin on its receptor is in some way inhibited by the large dimeric molecule of the ionic LOCM, yet activation of the receptor by the tethered ligand is unaffected. Thrombin is considered to be a cellular mitogen1 for smooth muscle cells, causing them to migrate and proliferate in the wall of the PTCAdamaged vessel. A contrast medium that attenuates the mitogenic effect might influence the post-PTCA healing process and thus reduce or alter the subsequent restenosis. The release of platelet-derived factors within the lumen of the balloon-damaged coronary artery during PTCA may influence the intracoronary prothrombotic environment and the stimulus to smooth muscle cell recruitment and proliferation, hypothesized to be part of the underlying mechanism in the restenosis process that occurs in 35% to 50% of patients after PTCA. Local dissections caused by the PTCA procedure would be likely to increase the contact time of the blood and contrast media and therefore enhance local release of these prothrombotic and vasoactive substances.
Conclusions
These studies have shown that routinely used contrast media cause significantly different degrees of platelet degranulation, as seen by flow cytometric analysis of individual platelets in whole blood. The nonionic LOCM Omnipaque caused profound platelet degranulation by a mechanism that appears to be related to the nonionic structure of compound rather than the osmolality of the medium. It is likely that this finding will be seen with all contrast media based on a nonionic molecular structure. The degranulation caused was independent of thrombin generation and was not blocked by pretreatment with heparin or aspirin. The degranulation was paralleled by release of prothrombotic factors from the platelet a-granule. These findings are consistent with previous reports of an increased incidence of thrombotic complications during coronary angiography and the development of clots in the angiography catheters and syringes reported with nonionic LOCM. [15] [16] [17] 32, 33 The potential beneficial effect of ionic LOCM that not only fails to cause platelet degranulation but also may modify the platelet response to intracoronary and clot bound thrombin is yet to be demonstrated in patients. These findings suggest that the choice of contrast media for angiography and PTCA in unstable coronary syndromes may influence the clinical outcome in these patients and suggest the need for studies to investigate whether these profound differences in platelet activation caused by contrast media in vitro are important in vivo.
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